Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults

• Main Authors: Marc Foca, Ram Yogev, Andrew Wiznia, Rohan Hazra, Patrick Jean-Philippe, Bobbie Graham, Paula Britto, Vincent J. Carey, Jennifer King, Edward P. Acosta, Tim R. Cressey
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969217101&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/56088
• Institution: Chiang Mai University

© 2016 Wolters Kluwer Health, Inc. Background: Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failur...